The Latest Cardiac and Vascular News
NEW YORK, Feb. 18, 2025 /PRNewswire/ — Remedy Pharmaceuticals, a leader in stroke drug development today announced efficacy data from the Phase 2 GAMES-RP and Phase 3 CHARM studies of CIRARA (intravenous glyburide) for the treatment of Large Hemispheric Infarction (LHI) presented at the…
February 10, 2025
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX) reported 12 month data from the Phase 2 study (SYCAMORE) of REC-994, the first industry sponsored Phase 2 trial completed in Cerebral Cavernous Malformations (CCM). The Company announced in September 2024 that the signal-finding study met its primary endpoint.
VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its wholly owned subsidiary, Algernon NeuroScience (AGN Neuro), has appointed Validcare as the contract research organization (“CRO”) for the Company’s upcoming randomized, double-blind, placebo-controlled Phase 2a DMT study of 40 stroke patients in Europe. The study is expected to begin enrolling patients in Q3 of 2025. Validcare is a leading U.S. based full service CRO with experience across a wide range of therapeutic indications.
MIAMI, Dec. 11, 2024 (GLOBE NEWSWIRE) — RapidPulse, Inc., a Delaware corporation headquartered in Miami, Florida focused on improving the treatment success rate for acute ischemic stroke (AIS) announced that the United States Food and Drug Administration (FDA) agreed that RapidPulse can begin enrollment in an Investigational Device Exemption (IDE) study of its novel and precise cyclic aspiration system. This will allow U.S. and European patient enrollment in 2025 to commence in a study designed to demonstrate the RapidPulse patented method of precisely pulsed aspiration is safe and effective in the treatment of AIS. RapidPulse’s technology is a spin-out of Syntheon 2.0, LLC, an innovative medical device incubator with a long track record of successful exits.
OTTAWA, ON, Nov. 15, 2024 /PRNewswire/ – Genomadix (genomadix.com), a global leader in point of need precision medicine diagnostics, announced today that it has entered into a know-how license agreement with Mayo Clinic to collaborate on the delivery of enhanced telestroke services in the…
NANJING, China, Oct. 25, 2024 /PRNewswire/ — On October 24, 2024, TASTE-2, a Chinese innovative stroke drug study led by Professor Wang Yongjun from Beijing Tiantan Hospital, was published in an oral report at the 16th World Stroke Conference (WSC): brain cell protection combined with…
NEW YORK, Oct. 22, 2024 /PRNewswire/ — Remedy Pharmaceuticals, a pioneer in stroke drug development, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Division (OOPD) has granted Orphan Drug Designation for CIRARA for the treatment of “large…
A First in the Middle East and North Africa
KFSHRC Launches Mobile Stroke Unit to Accelerate Patient Treatment
PORTAGE, Mich., USA, Sept. 20, 2024 /PRNewswire/ — Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the acquisition of NICO Corporation, a privately held company providing a systematic approach to minimally invasive surgery for tumor and…
